noribogaine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
noribogaine : An organic heteropentacyclic compound that is ibogamine in which the indole hydrogen para to the indole nitrogen has been replaced by a hydroxy group. It is the primary (and long-lived) metabolite of ibogaine, the psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe iboga. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Tabernanthe | genus | [no description available] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 3083548 |
| CHEBI ID | 146264 |
| SCHEMBL ID | 116220 |
| MeSH ID | M0248687 |
| Synonym |
|---|
| noribogaine |
| CHEBI:146264 |
| (18r)-ibogamine-12-ol |
| o-desmethylibogaine |
| SCHEMBL116220 |
| (-)-noribogaine |
| (1r,15r,17s,18s)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-ol |
| Q7051224 |
| DTXSID90963998 |
| PD133273 |
Noribogaine is an iboga alkaloid being studied for the treatment of opioid dependence.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Noribogaine is an iboga alkaloid being studied for the treatment of opioid dependence." | ( Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys. Accardi, MV; Arezzo, J; Authier, S; Friedhoff, LT; Gerson, RJ; Paquette, D; Pouliot, M; Stubbs, RJ; Weis, H, ) | 1.12 |
Noribogaine displays atypical opioid-like components in vivo. It caused a 170% increase above basal [35S]GTPgammaS binding at sub-micromolar effective concentrations (EC50) This effect was an opioid receptor-mediated process.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Noribogaine displays atypical opioid-like components in vivo, anti-addictive effects and potent modulatory properties of the tolerance to opiates for which the mode of action remained uncharacterized thus far." | ( Noribogaine is a G-protein biased κ-opioid receptor agonist. Fishback, J; Garamszegi, N; Heghinian, MD; Maillet, EL; Mash, DC; Milon, N; Schürer, SC, 2015) | 2.58 |
| "Noribogaine caused a 170% increase above basal [35S]GTPgammaS binding at sub-micromolar effective concentrations (EC50) in a naloxone-sensitive manner, confirming that this effect was an opioid receptor-mediated process." | ( Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Mash, DC; Pablo, JP, 1998) | 2.46 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Noribogaine-treated rats did not display place preference, suggesting that noribogaine is not perceived as a hedonic stimulus in rodents." | ( Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. Ameer, B; Howes, JF; Maillet, EL; Mash, DC; Prou, D, 2016) | 1.67 |
Single oral doses of noribogaine 3-60 mg were safe and well tolerated in healthy volunteers. In the current study, a norIBogaine dose of 320mg/kg was considered to be the EEG no observed adverse effect level (NOAEL) in conscious freely moving cynomolgus monkeys.
The objectives of this Phase I study were to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of noribogaine.
| Excerpt | Reference | Relevance |
|---|---|---|
| " These data show that there are sex differences in the effects of ibogaine and that this may be due to decreased bioavailability of ibogaine in males as compared to females." | ( Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Boyd, DL; Glick, SD; Hough, LB; Pearl, SM, 1997) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Subjects established on daily methadone OST (mean dose 60 mg/day) were switched to morphine slow-release capsules, dosed at 4× the previous total daily methadone dose, for 6 days, then given morphine syrup dosed q3h." | ( Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. Cape, G; Devane, J; Friedhoff, L; Glue, P; Gray, A; Harland, S; Howes, J; Hung, CT; Hung, N; Lam, F; Lockhart, M; Tunnicliff, D; Weis, H, 2016) | 0.43 |
| ", 160 and 320mg/kg, PO) with an interval between dosing of at least 6days, and the resulting behavioral and EEG effects were evaluated." | ( Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys. Accardi, MV; Arezzo, J; Authier, S; Friedhoff, LT; Gerson, RJ; Paquette, D; Pouliot, M; Stubbs, RJ; Weis, H, ) | 0.4 |
| Role | Description |
|---|---|
| psychotropic drug | A loosely defined grouping of drugs that have effects on psychological function. |
| serotonin uptake inhibitor | A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. |
| NMDA receptor antagonist | Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs. |
| kappa-opioid receptor agonist | A compound that exhibits agonist activity at the kappa-opioid receptor. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monoterpenoid indole alkaloid | A terpenoid indole alkaloid which is biosynthesised from L-tryptophan and diisoprenoid (usually secolaganin) building blocks. |
| organic heteropentacyclic compound | |
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (37.25) | 18.2507 |
| 2000's | 10 (19.61) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (11.54%) | 5.53% |
| Reviews | 4 (7.69%) | 6.00% |
| Case Studies | 3 (5.77%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 39 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||